Generic Name and Formulations:
Cosyntropin 0.25mg/mL; pwd for IV or IM inj after reconstitution; preservative-free.
Amphastar Pharmaceuticals, Inc.
Indications for CORTROSYN:
For use in the screening of patients presumed to have adrenocortical insufficiency.
Adults and Children:
Give by IV, IM inj or IV infusion over 4–8hrs. <2yrs: 0.125mg. ≥2yrs: Usual range: 0.25–0.75mg.
Patients with raised bilirubin or where plasma contains free hemoglobin: falsely high fluorescence measurements may result. Pregnancy (Cat.C). Nursing mothers.
May accentuate the electrolyte loss associated with diuretics. May exhibit abnormally high plasma cortisol levels if patients taking cortisone, hydrocortisone, spironolactone, estrogens.
Hypersensitivity reactions (eg, rare, but possible), bradycardia, tachycardia, hypertension, peripheral edema, rash.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|